Please login to the form below

Not currently logged in
Email:
Password:

pertuzumab

This page shows the latest pertuzumab news and features for those working in and with pharma, biotech and healthcare.

Hemlibra off to a flyer as Roche raises 2019 forecasts

Hemlibra off to a flyer as Roche raises 2019 forecasts

It’s looking likely to overtake Roche’s older breast cancer Perjeta (pertuzumab), which rose 41% to CHF 868m in the quarter and has been another big growth driver for the

Latest news

  • AZ makes $6.9bn play for Daiichi Sankyo HER2 drug AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

    trastuzumab) and Perjeta (pertuzumab), and have disease progression after Kadcyla treatment. ... Current treatment guidelines for patients with HER2 positive metastatic breast cancer recommend the combination of trastuzumab, pertuzumab and a taxane as

  • Biosimilar Herceptin helps Roche gain new Perjeta recommendation Biosimilar Herceptin helps Roche gain new Perjeta recommendation

    considerably. The cost effectiveness watchdog has today recommended Roche’s newer breast cancer treatment Perjeta (pertuzumab) in people with early HER2-positive breast cancer whose disease has spread to their lymph ... The NICE document indicates this

  • Ocrevus helps Roche shrug off biosimilars in 2018 Ocrevus helps Roche shrug off biosimilars in 2018

    All told, new products accounted for 90% of Roche’s sales growth in 2018, with another big boost provided by the company’s breast cancer drug Perjeta (pertuzumab), up 27% to

  • Roche preps new Kadcyla filings after phase 3 trial win Roche preps new Kadcyla filings after phase 3 trial win

    Neoadjuvant therapy is given with the intention of achieving a cure for patients with early-stage cancer, and Herceptin and follow-up HER2 drug Perjeta (pertuzumab) have been approved for this ... With Herceptin and follow-up Perjeta (pertuzumab) already

  • Ocrevus surge keeps Roche smiling in Q3 Ocrevus surge keeps Roche smiling in Q3

    However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led

More from news
Approximately 6 fully matching, plus 50 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics